“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药

格隆汇2023-11-24

随着近期减肥药的热度飙升，民营疫苗巨头智飞生物也将进军糖尿病、肥胖等疾病领域。11月23日晚间，公司发布公告称，拟以现金收购智睿投资、张高峡持有的重庆宸安生物制药有限公司(简称“宸安生物”)100%股权并签署股权收购意向性协议。公告称，本次交易完成后，宸安生物将成为公司的全资子公司。公司业务版图延伸覆盖至糖尿病、肥胖等代谢类疾病领域，并以宸安生物为主体拓展进入治疗类生物制药领域。不过智飞生物也提醒...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2385604444?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg","is_english":false,"pubTime":"2023-11-24 11:51","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2385604444","market":"sg","top_or_hot":-1,"title":"“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药","media":"格隆汇","content":"<div>\n<p>随着近期减肥药的热度飙升，民营疫苗巨头智飞生物也将进军糖尿病、肥胖等疾病领域。11月23日晚间，公司发布公告称，拟以现金收购智睿投资、张高峡持有的重庆宸安生物制药有限公司(简称“宸安生物”)100%股权并签署股权收购意向性协议。公告称，本次交易完成后，宸安生物将成为公司的全资子公司。公司业务版图延伸覆盖至糖尿病、肥胖等代谢类疾病领域，并以宸安生物为主体拓展进入治疗类生物制药领域。不过智飞生物也提醒...</p>\n\n<a href=\"https://www.gelonghui.com/p/667485\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-24 11:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/667485><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>随着近期减肥药的热度飙升，民营疫苗巨头智飞生物也将进军糖尿病、肥胖等疾病领域。11月23日晚间，公司发布公告称，拟以现金收购智睿投资、张高峡持有的重庆宸安生物制药有限公司(简称“宸安生物”)100%股权并签署股权收购意向性协议。公告称，本次交易完成后，宸安生物将成为公司的全资子公司。公司业务版图延伸覆盖至糖尿病、肥胖等代谢类疾病领域，并以宸安生物为主体拓展进入治疗类生物制药领域。不过智飞生物也提醒...</p>\n\n<a href=\"https://www.gelonghui.com/p/667485\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300122","symbol_name":"智飞生物","start_time":0,"source_url":"https://www.gelonghui.com/p/667485","article_id":"2385604444","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2385604444","pubTimestamp":1700797865,"columns":[],"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"A股减肥药概念或再添新军","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300122":"智飞生物","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","BK4585":"ETF&股票定投概念","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","BK0239":"医药制造","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","MRK":"默沙东","BK0077":"质押式回购","BK4516":"特朗普概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4559":"巴菲特持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK0046":"生物疫苗","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4550":"红杉资本持仓","BK0188":"融资融券","SG9999014542.SGD":"United Income Focus Trust Acc SGD","GSK":"葛兰素史克","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4588":"碎股","LU0861579265.USD":"联博低波幅策略股票基金A","BK4007":"制药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","GSK.UK":"葛兰素史克","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4532":"文艺复兴科技持仓","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4534":"瑞士信贷持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK0196":"行业龙头","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD"},"translate_title":"After \"left-handed Merck, right-handed GSK\", 160 billion vaccine giants have to rush to the beach for diet pills","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":0.9,"MRK":1,"GSK.UK":0.6,"GSK":1},"content_text":"随着近期减肥药的热度飙升，民营疫苗巨头智飞生物也将进军糖尿病、肥胖等疾病领域。11月23日晚间，公司发布公告称，拟以现金收购智睿投资、张高峡持有的重庆宸安生物制药有限公司(简称“宸安生物”)100%股权并签署股权收购意向性协议。公告称，本次交易完成后，宸安生物将成为公司的全资子公司。公司业务版图延伸覆盖至糖尿病、肥胖等代谢类疾病领域，并以宸安生物为主体拓展进入治疗类生物制药领域。不过智飞生物也提醒，该交易尚处于筹划阶段，交易价格等关键事项均未定，交易是否最终实施尚存在不确定性。另外，值得一提的是，宸安生物为智飞生物实际控制人蒋仁生所控制的企业，根据相关规定，公司收购宸安生物100%股权事项构成关联交易，但预计不构成重大资产重组情形。向糖尿病、肥胖等领域延伸资料显示，宸安生物聚焦糖尿病、肥胖等代谢类疾病领域，已形成梯次分明的GLP-1类似药物、胰岛素类似物管线布局。目前，宸安生物有6款已进入临床阶段的候选药物，其中重组利拉鲁肽注射液、德谷胰岛素注射液已完成临床Ⅲ期，位于申报上市阶段；管线重组司美格鲁肽注射液已位于临床Ⅲ期阶段，研发进度处于国内前列。此外，宸安生物布局的GLP-1/GIP双靶点受体激动剂、口服司美格鲁肽片等在研管线位于临床前阶段。同时，宸安生物持续建设生产基地以满足产品开发和规模化生产的需求，已建成1个制剂车间和2个原料药车间。而业内有“疫苗茅”之称的智飞生物则是一家集疫苗、生物制品研发、生产、销售、配送及进出口为一体的国际化、全产业链高科技生物制药企业。目前公司共有11种产品上市在售，1种产品附条件上市，包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品，也涵盖提供结核感染诊断、预防、治疗解决方案的药品。过去几年，智飞生物因为独家代理默沙东的HPV疫苗受到多方关注，业绩一度迎来腾飞。2019年-2021年，智飞生物净利润的同比增长率分别高达 63.05%、39.51%、 209.22%。2022年全年智飞生物的营业收入达到382.64亿元，净利润为75.39亿元。较前几年虽然智飞生物的营收规模及净利润仍处于高位，但净利润的负增长让外界担忧其延续多年的高成长性将终结。对于净利润同比减少原因，智飞生物在2022年报中解释称，受客观因素影响，公司部分产品的市场需求和竞争格局发生了较大变化，其销量与去年相比有明显下降。对此市场普遍的看法是，近两年随着国产九价HPV疫苗加速上市，令公司未来代理产品面临更严峻的市场竞争。就2023年三季报来看，今年前9月，公司实现营业收入392.72亿元，同比增长41.15%；净利润65.3亿元，同比增长16.46%；扣除净利润63.8亿元，增幅14.13%。公司净利润虽然重拾升势，但增速远不如之前。拥有默沙东、GSK两大独家代理权在已有业绩增速放缓的背景下，智飞生物今年大招频出。今年1月份，智飞生物就曾与默沙东签了“千亿元大单”，向默沙东持续采购HPV疫苗、五价轮状病毒疫苗等协议产品，再一次在九价HPV疫苗等市场站稳了脚跟。10月份，公司因一举拿下GSK(葛兰素史克公司)的带状疱疹疫苗的独家代理权而备受市场关注。业内普遍认为，拥有“左手默沙东、右手GSK”独家代理权的智飞生物，未来业绩盈利空间有望进一步打开。股价方面，作为曾经首屈一指的白马股，智飞生物曾在2016到2021年创造了5年涨近20倍的神话，市值一度近4000亿。但从2021年5月高点至今，其股价累积跌幅已超70%。最近的几个月公司股价才刚有抬头趋势，目前最新市值维持在1600亿左右。在疫苗代理领域拥有默沙东、GSK两大独家代理权之后，如今智飞生物又大举进攻糖尿病、肥胖等代谢类疾病领域，其股价后续会有什么惊喜的表现吗？","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2385604444","isCrawlerRequest":true}